Document is current

Article History

Received: 7 December 2022

Accepted: 1 February 2023

First Online: 18 February 2023

Declarations

:

: M. Thill: <i>consult/advisory role:</i> Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Biom ‘Up, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal, GSK, Lilly, MSD, Norgine, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm Medical, Pierre-Fabre, Roche, RTI Surgical, Seagen, Sirius Pintuition and Sysmex; <i>manuscript support</i>: Amgen, ClearCut, Clovis, pfm medical, Roche and Servier; <i>travel expenses:</i> Amgen, Art Tempi, AstraZeneca, Clearcut, Clovis, Connect Medica, Daiichi Sankyo, Eisai, Exact Sciences, Hexal, I-Med-Institute, Lilly, MCI, Medtronic, MSD, Neodynamics, Norgine, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical and Seagen; <i>congress support</i>: Amgen, AstraZeneca, Celgene, Daiichi Sanyko, Hexal, Neodynamics, Novartis, Pfizer and Roche; <i>lecture honoraria</i>: Amgen, Art Tempi, AstraZeneca, Clovis, Connect Medica, Eisai, Exact Sciences, Gedeon Richter, Gilead Science, GSK, Hexal, I-Med-Institute, Jörg Eickeler, Laborarztpraxis Walther et al., Lilly, MCI, Medscape, MSD, Medtronic, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, StreamedUp, Sysmex, Vifor and Viatris; <i>trial funding</i>: Endomag and Exact Sciences and <i>trial honoraria</i>: AstraZeneca, Biom’Up, Celgene, Clearcut, Neodynamics, Novartis, pfm medical, Roche and RTI Surgical. A. Welt: <i>Salary</i>: University Hospital Essen, Germany and <i>consult/advisory role:</i> Amgen, Daiichi Sankyo, Eisai, Interplan, Lilly, MCI, MSD, Novartis, Pfizer, Roche and Seagen. E. Stickeler: Receipt of intellectual property rights/patent holder; <i>consultant/advisory role:</i> Astra Zeneca, Novartis, Roche and Trinovis. J. Rauh: Remuneration for participation in clinical trials. N. Marschner: <i>stock ownership and upper management responsibility</i> (iOMEDICO), <i>consultant/advisory role:</i> Amgen, Celgene, Lilly, Mundipharma, Mylan, Novartis, Pfizer and Roche; <i>contracted research:</i> Amgen, Celgene, Lilly, Mundipharma, Mylan, Pfizer and Roche. N. Harbeck: <i>consultant/advisory role:</i> Astra Zeneca, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz and Seagen; <i>fees for non-CME Services Received Directly from Commercial Interest or their Agents (e.g. speakers' bureaus)</i>: Amgen, Astra Zeneca, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer and Roche; <i>ownership interest</i>: West German Study Group; <i>contracted research</i>: all to institution. A. Wöckel: <i>consultant/advisory role</i>: Amgen, AstraZeneca, Celgene, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead, Hexal, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagan, Sirtex, Tesaro and Teva. T. Decker: <i>consultant/advisory role</i>: Novartis and iOMEDICO. T. Fietz, M. Jänicke, L. Kruggel, A. Nusch, N. Wetzel and M.-O. Zahn declare no conflict of interest concerning the topic of this publication.

: This study was conducted and analyzed in accordance with the ethical standards of the national research committee and the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: Written informed consent was obtained from all individual participants included in the study.

: Not applicable.